Boston Scientific Corporation
BSX
$100.02
$0.970.98%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 55.72% | 37.09% | 14.60% | 16.38% | 46.01% |
| Total Depreciation and Amortization | 9.48% | 7.08% | 6.17% | 6.10% | 4.84% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -25.53% | -44.94% | 85.36% | 59.92% | 129.97% |
| Change in Net Operating Assets | 90.87% | 103.80% | 59.90% | 40.00% | -122.43% |
| Cash from Operations | 57.56% | 62.80% | 53.90% | 37.24% | 24.78% |
| Capital Expenditure | -2.82% | -1.14% | -2.44% | -11.11% | -18.90% |
| Sale of Property, Plant, and Equipment | -- | 100.00% | 100.00% | -50.00% | -100.00% |
| Cash Acquisitions | -144.27% | -552.36% | -225.83% | -156.21% | -97.94% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 54.36% | -29.69% | -140.35% | -362.50% | -487.80% |
| Cash from Investing | -92.09% | -274.14% | -148.51% | -120.94% | -78.17% |
| Total Debt Issued | -18.55% | -17.13% | -18.55% | -- | -- |
| Total Debt Repaid | -247.83% | -204.88% | -145.97% | -13,125.00% | -13,125.00% |
| Issuance of Common Stock | 32.42% | 36.87% | 33.17% | 26.37% | 19.02% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | 100.00% |
| Other Financing Activities | 11.82% | -87.25% | -44.81% | -52.41% | -48.65% |
| Cash from Financing | -99.81% | -92.98% | -70.91% | 36,180.00% | 18,044.44% |
| Foreign Exchange rate Adjustments | 1,400.00% | 522.22% | 418.18% | -175.00% | 140.00% |
| Miscellaneous Cash Flow Adjustments | -- | -200.00% | -- | -- | -100.00% |
| Net Change in Cash | -177.39% | -195.05% | -191.00% | -542.86% | 138.52% |